Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Ania M JastreboffLee M KaplanJuan Pablo FriasQiwei WuYu DuSirel GurbuzTamer CoskunAxel HauptZvonko MilicevicMark L Hartmannull null

Published in: The New England journal of medicine (2023)

In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).

Keyphrases

body weight
insulin resistance
metabolic syndrome
weight loss
high fat diet induced
type diabetes
weight gain
adipose tissue
skeletal muscle
body mass index
gestational age
replacement therapy